Articles
21.06.2021
UK the next hub for Biosimilars

Biosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...

Read more
Articles
16.06.2021
Early market access in France is changing

France's new Social Security Financing Bill (SSFB) will be coming into place no later than July 1st.

Read more
Articles
02.06.2021
EU Joint HTA EESC publish its positive option

Are we one step closer to an EU Health Technology Assessment body. The EESC publish its positive opi...

Read more
Articles
26.05.2021
Better internal communications

4 ways to improve market access through communication

Read more
Articles
21.05.2021
Cross-functional collaboration

There is a large opportunity many companies are still yet to seize in this area.

Read more
Articles
20.05.2021
What is HST

NICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...

Read more
Articles
12.05.2021
NICE 5-year strategy

NICE has set out its plan using four key pillars designed to elicit incremental change within the UK...

Read more
Articles
11.05.2021
Market access training for speciality products

Securing patient access in specialty products is becoming increasingly challenging due to the comple...

Read more
Articles
04.05.2021
What is the difference between RWE & RWD

Real-world evidence (RWE) is increasingly playing an important role in developing product value prop...

Read more
Articles
28.04.2021
Managed access agreements NICE process

The highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.